Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

What Awaits ACUR & Other Drug Stocks This Earnings Season?

By Zacks Investment ResearchStock MarketsJul 28, 2016 09:43PM ET
www.investing.com/analysis/what-awaits-acur---other-drug-stocks-this-earnings-season-200144988
What Awaits ACUR & Other Drug Stocks This Earnings Season?
By Zacks Investment Research   |  Jul 28, 2016 09:43PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Getting into the thick of the Q2 earnings season, we have seen releases from 208 S&P 500 members, accounting for 50.5% of the index’s total market capitalization, as of Jul 27. As per our Earnings Trend report, earnings for these companies have declined 4.7% on a year-over-year basis on 0.4% higher revenues. In spite of bleak year-over-year comparisons, a whopping 73.1% were able to surpass earnings estimates, while 51.9% beat on revenues.

Although Q2 is still on track to be the fifth quarter in a row to record negative earnings growth, the rate of growth is showing modest improvement from last quarter. Going forward, even though estimates for the third quarter are still moving south, the magnitude of the fall has lessened down.

Medical is one of the six sectors that are projected to record positive earnings growth this quarter. Earnings in the sector are expected to increase 2.3% on revenue growth of 7.7%. Within the S&P 500 index, 36.5% of the companies in the Medical sector have reported results so far, putting up an average earnings decline of 0.3% on 12.6% higher revenues and resulting in a blended beat of 78.9%. Bigwigs like Johnson & Johnson (NYSE:JNJ) , Novartis AG (NYSE:NVS) and Abbott Laboratories (NYSE:ABT) were able to beat expectations comfortably. In the biotech space, Gilead Sciences (NASDAQ:GILD) missed on revenues in spite of an earnings beat, while Biogen (NASDAQ:BIIB) topped bottom-line estimates.

Let’s see what’s in store for a few companies that are scheduled to report results early next week.

Illinois-based Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is scheduled to report second-quarter 2016 results on Aug 1. The specialty pharmaceutical company is engaged in the development and commercialization of technologies and products for addressing medication abuse and misuse. The company uses its three proprietary platform technologies – Aversion, Limitx and Impede – to develop multiple products. Acura has a dismal track record so far, having missed estimates in the past two quarters. For this quarter, the company has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%, which makes surprise prediction difficult.

ACURA PHARMACT Price and Consensus

ACURA PHARMACT Price and Consensus | ACURA PHARMACT Quote

North Carolina-based Cempra, Inc. (NASDAQ:CEMP) is expected to report second-quarter earnings on Aug 1. This clinical-stage pharmaceutical company focuses on developing differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. Its lead candidate, solithromycin, is being developed for the treatment of community acquired bacterial pneumonia (CABP). The FDA has accepted the company’s New Drug Application (NDA) on the candidate. The company has a mixed track record. The combination of Cempra’s Zacks Rank #3 and0.00% Earnings ESP makes surprise prediction difficult this quarter.

CEMPRA INC Price and EPS Surprise

CEMPRA INC Price and EPS Surprise | CEMPRA INC Quote

CytRx Corporation (NASDAQ:CYTR) is expected to report second-quarter results on Aug 1. The biopharmaceutical company specializes in the field of oncology. The company is currently focused on the clinical development of aldoxorubicin, a modified version of the chemotherapeutic agent, doxorubicin. The company is also evaluating the candidate as a second-line treatment for small cell lung cancer, HIV-related Kaposi's sarcoma and late-stage glioblastoma (brain cancer) among other indications. The company has an encouraging track record, having beaten estimates in three of the last four quarters. For the to-be-reported quarter, CytRx has a Zacks Rank #1 (Strong Buy) and an Earnings ESP of +15.00%, which makes us reasonably confident of an earnings beat this quarter.

CYTRX CORP Price and EPS Surprise

CYTRX CORP Price and EPS Surprise | CYTRX CORP Quote

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) is expected to report second-quarter 2016 results on Aug 1. Nivalis, a development-stage pharmaceutical company, is focused on the discovery, development and commercialization of treatments for cystic fibrosis. Nivalis’ performance has been disappointing so far. In the four trailing quarters, the company has missed expectations thrice, and met the same once, bringing the average negative surprise to 71.27%. Nivalis currently carries a Zacks Rank #2 (Buy), which when combined with its Earnings ESP of 0.00%, makes surprise prediction difficult. (Read: Nivalis (NVLS): Can the Stock Surprise This Earnings Season?)

NIVALIS THERAPT Price and EPS Surprise



NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

CYTRX CORP (CYTR): Free Stock Analysis Report

ACURA PHARMACT (ACUR): Free Stock Analysis Report

NIVALIS THERAPT (NVLS): Free Stock Analysis Report

CEMPRA INC (CEMP): Free Stock Analysis Report

Original post

Zacks Investment Research
What Awaits ACUR & Other Drug Stocks This Earnings Season?
 

Related Articles

What Awaits ACUR & Other Drug Stocks This Earnings Season?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email